Sisomicin


Generic Medicine Info
Indications and Dosage
Intramuscular
Susceptible Gram-negative infections, Susceptible staphylococcal infections
Adult: 3 mg/kg daily in 2-3 divided doses. May also be given as IV infusion, if needed.

Topical/Cutaneous
Pyoderma
Adult: As 0.1% cream: Apply onto the affected area(s) bid.
Renal Impairment
Intramuscular:
May need to adjust maintenance doses and/or dosing intervals.
Contraindications
Hypersensitivity.
Special Precautions
Renal or liver impairment, myasthenia gravis, parkinsonism, dehydration, hypotension, pregnancy, lactation.
Adverse Reactions
Ototoxicity, nephrotoxicity, neurotoxicity (peripheral neuropathy, confusion, lethargy, hallucination, convulsion and mental depression, occasional respiratory depression), rarely hypersensitivity reaction.
Potentially Fatal: Acute renal failure especially in combination with other nephrotoxic drugs.
Drug Interactions
Plasma levels increased by indometacin. Antihistamines (H1-receptor blocker) may mask early signs of ototoxicity. Incompatible with some β-lactam antibiotics.
Potentially Fatal: Potentiates nephrotoxicity produced by other nephrotoxic drugs including other aminoglycosides, vancomycin and some cephalosporins. Potentiates ototoxicity produced by other aminoglycosides, ethacrynic acid. Ototoxicity potentiated by furosemide.
Action
Description: Sisomicin binds to 30s and 50s ribosomal subunits of susceptible bacteria disrupting protein synthesis, thus rendering the bacterial cell membrane defective.
MIMS Class
Aminoglycosides
Disclaimer: This information is independently developed by MIMS based on Sisomicin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in